PharmacoEconomics

1997 - 2026

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 44, issue 5, 2026

Subgroup Modelling and Use of External Evidence in Precision Oncology Appraisals: An External Assessment Group Perspective on the NICE Single Technology Appraisal of Zolbetuximab for Untreated CLDN18.2-Positive HER2-Negative Unresectable Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma pp. 509-513

Mirre Scholte, Andrea Fernández Coves, Huiqin Yang, Nigel Armstrong, Kevin McDermott, Xiaoyu Tian, Lisa Stirk, Robert Wolff, Manuela A. Joore and Sabine E. Grimm

The Value of Combination Vaccines in Children and Adults: More than the Sum of Their Parts pp. 515-516

Anthony T. Newall

Estimating the Value of Combination Vaccines: A Methodological Framework pp. 517-526

Mark Jit, Allison Portnoy, Clint Pecenka, William P. Hausdorff and Christopher Gill

Patient-Level Health Economic Modeling in Excel Without VBA: A Tutorial pp. 527-538

Rob Blissett, Will Sullivan, Inola Subban and Adam Igloi-Nagy

A Modern Approach for Constructing Decision Analytic Models in Microsoft Excel pp. 539-558

Mike Paulden

A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives pp. 559-583

Josep Darbà, Meritxell Ascanio and Antonio Rodríguez

Innovative Contracting for Gene Therapies: Current Landscape and Perspectives on the Future of Gene Therapy Financing in the USA pp. 585-598

Tyler D. Wagner, Jacqlyn W. Riposo, Kendra M. Gould, Jonathan D. Campbell, James T. Kenney, Claire M. Csenge and Theresa Schmidt

Are Health Gains to Children and Adolescents More Important Than Health Gains to Adults? A Person Trade-Off Study pp. 599-613

Tessa Peasgood, Udeni De Silva Perera, Gang Chen, Cate Bailey, Richard Norman, Rosalie Viney, Koonal Shah and Nancy Devlin

The Cost Effectiveness of Upgrading Cochlear Implant Sound Processors in Australia: A Novel Application of Individual-Level Microsimulation Models pp. 615-638

Bonny Parkinson, Elizabeth Seil, Rajan Sharma, Paola Incerti, Jason Gavrilis, Antonio Ahumada-Canale and Padraig Kitterick

Comment on “The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective” pp. 639-640

Dyfrig A. Hughes

Response to Comment on “The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective” pp. 641-642

Hangjian Wu, Cristina Fernandez-Garcia and Stephen Rice

Correction: Estimating the Value of Combination Vaccines: A Methodological Framework pp. 643-646

Mark Jit, Allison Portnoy, Clint Pecenka, William P. Hausdorff and Christopher Gill

Volume 44, issue 4, 2026

Lowering the Barriers to the Appropriate Use of Individual-Level Simulation for Health Economic Evaluation pp. 375-377

Salah Ghabri, Jonathan Karnon and J. Jaime Caro

Microsimulation Modeling for Health Decision Sciences Using C++: A Tutorial pp. 379-387

Aku-Ville Lehtimäki and Janne Martikainen

Beyond the States: Developing a Discrete Event Simulation Model Using R pp. 389-408

Ziyi Lin and Andrew Briggs

Discrete-Event Simulation Modeling Framework for Cancer Interventions and Population Health in R (DESCIPHR): An Open-Source Pipeline pp. 409-427

Selina Pi, Carolyn M. Rutter, Carlos Pineda-Antunez, Jonathan H. Chen, Jeremy D. Goldhaber-Fiebert and Fernando Alarid-Escudero

Comparing the Influence of Heterogeneity on Model Outcomes in Individual-Level and Cohort Simulations: An Exploratory Simulation Study pp. 429-437

Evelien B. van Well, Tim M. Govers and Hendrik Koffijberg

Individualized Treatment Rules Based on Cost-Effectiveness Criteria in Microsimulations pp. 439-450

Niklaus Meier, Ana Cecilia Quiroga Gutierrez, Mark Pletscher and Matthias Schwenkglenks

Deriving an Analytical Solution to Inversion of Royston/Parmar Restricted Cubic Spline Parametric Survival Models for Discrete Event Simulation pp. 451-459

George Bungey, Jorgen Moller, James Saunders and Venediktos Kapetanakis

Developing and Calibrating a Colorectal Cancer Microsimulation Model for Northern Ireland pp. 461-475

Olivia Adair, Ethna McFerran, Mark Lawler, Luuk A. van Duuren and Felicity Lamrock

Spectrum of Models for Assessing the Cost Effectiveness of Total Knee Replacement Implants: A Comparison of Discrete-Time Cohort Markov and Continuous-Time Individual-Level Multistate Models pp. 477-494

Yixin Xu, Elsa M. R. Marques, Nicky J. Welton, Linda P. Hunt, Michael Whitehouse, Ashley W. Blom, Andrew D. Beswick and Howard H. Z. Thom

Development of a Patient-Level Multi-objective Optimisation Model for Screening Strategies for Childhood Type 1 Diabetes pp. 495-507

Gonçalo Leiria, R. Brett McQueen, Conner Jackson, Marian Rewers, William A. Hagopian, Richard A. Oram, Jonathan E. Fieldsend and Lauric A. Ferrat

Volume 44, issue 3, 2026

The Importance of Structured Expert Elicitation to Inform Outcomes Following Treatment Discontinuation: Evidence Assessment Group Perspective pp. 263-266

Hangjian Wu, Cristina Fernandez-Garcia, Nicole O’Connor, Oleta Williams, Sola Akinbolade, Ayomikun Ogunyemi, Sonia Garcia Gonzalez-Moral, Fiona Beyer, Nick Meader and Stephen Rice

EQ-5D(-Y) Valuation from Adult and Child Perspectives: Where Does the Empirical Evidence Leave Us and How Should We Proceed? pp. 267-278

Stefan A. Lipman and Zhirui Guo

Practical Considerations for Incorporating Equity More Explicitly in Australian Health Technology Assessment Processes pp. 279-286

Anagha Killedar, Martin Howell, Kirsten Howard and Sarah Norris

Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review pp. 287-298

Tien Hoang Tran and Hyung Seok John Kim

Economic Evaluations of Medication Safety Interventions in Primary and Long-Term Care: A Systematic Review pp. 299-316

Sneha T. Amritlal, Rosalyn Chandler, Alireza Mahboub-Ahari, Luke Paterson, Anthony J. Avery, Darren M. Ashcroft, Antony Chuter and Rachel A. Elliott

A Method for Comparing Health Inequality Impact Magnitudes, with an Illustration for Hypothetical Treatments of 1336 Diseases pp. 317-328

Richard Cookson, Gunjeet Kaur, Ieva Skarda, Shrathinth Venkatesh, Tim Doran, Ole F. Norheim, Mike Paulden and Owen O’Donnell

Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial pp. 329-341

Martin Bøg, Anders Bo Bojesen, Scott Emerson, Milana Ivkovic, Nia C. Jenkins, Christopher Lübker, Muhammad Mamdani, Thomas Padgett, Luc Van Gaal, Peter E. Weeke and A. Michael Lincoff

Public Health Impact and Cost-Effectiveness of Routine and Catch-Up Human Papillomavirus Vaccination in Girls and Women in Selected Regions of China: A Model-Based Study pp. 343-357

Xiaoya Fu, Qian Zhang, Abram L. Wagner, Ye Yao, Yilan Xia, Fengge Wang and Yihan Lu

Bevacizumab for Metastatic Colorectal Cancer with Chromosomal Instability: Cost-Effectiveness Analysis for a Novel Precision Treatment Approach in Germany, Ireland and Spain pp. 359-374

Jonathan Briody, Ian S. Miller, James F. O’Mahony, Lesley Tilson, Alice C. O’Farrell, Qiushi Chen, Verena Murphy, Orla Casey, Nadine Schulte, Matthias P. Ebert, Jochen H. M. Prehn, Diether Lambrechts, Bauke Ylstra, Rodrigo Dienstmann, Annette T. Byrne and Kathleen Bennett

Volume 44, issue 2, 2026

Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease pp. 105-113

Matthew Walton, Nyanar J. Deng, Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah J. Nevitt, Helen Fulbright, Chong Yew Tan, Robin Lachmann, Rachel Churchill and Robert Hodgson

The ‘Values in Modelling’ Framework for Patient and Public Involvement in Health Economics Modelling: Development and Application in the LEAP Model Project pp. 115-139

Stephanie Harvard, Rachel Carter, Sian Hoe Cheong, Tony Lanier, Zainab Zeyan, Amin Adibi, Spencer Lee, Cristina Novacovik, Mark Ewert, Eric B. Winsberg and Kate M. Johnson

Improving Collaborative Engagement in Health State Valuation: A Scoping Review of Current Practices and Emerging Recommendations pp. 141-163

Philip A. Powell, Victoria Gale, Gurdas Singh, Anthea Sutton, Janine Verstraete, Nancy Devlin, Michael Herdman, Simone Schieskow and Jill Carlton

A Systematic Review of Decision-Analytic Modelling Approaches in Economic Evaluations of Post-traumatic Stress Disorder Treatments pp. 165-185

Sheradyn R. Matthews, Laura C. Edney and Reginald D. V. Nixon

Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria pp. 187-205

Ziwen Zhao, Zhao Shi, Lei Dou, Chaofan Li and Shunping Li

Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA pp. 207-218

Amy Dymond, Alix Arnaud, Ion Agirrezabal and Will Green

External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost Effectiveness pp. 219-231

Christopher G. Fawsitt, Howard Thom, David Aceituno, Alexander Jarde, Sara Larsen, Christopher Lübker, Edward Kayongo, Edna Keeney and Volker Foos

Health-Service Costs for the Treatment of Multidrug-Resistant/Rifampicin-Resistant Tuberculosis in South African Children: Application of a Real-World Dataset pp. 233-244

Thomas Wilkinson, Arne von Delft, Anneke C. Hesseling, Edina Sinanovic, H. Simon Schaaf and James A. Seddon

Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective pp. 245-259

Isabell Wiethoff, Willem J. A. Witlox, Silvia M. A. A. Evers, Michelle Michels and Mickaël Hiligsmann

Correction: Cost Effectiveness of Exclusionary EGFR Testing for Taiwanese Patients Newly Diagnosed with Advanced Lung Adenocarcinoma pp. 261-261

Huang-Tz Ou, Jui-Hung Tsai, Yi-Lin Chen, Tzu-I. Wu, Li-Jun Chen and Szu-Chun Yang

Volume 44, issue 1, 2026

Economic Consequences of Increasing the NICE Cost-Effectiveness Threshold pp. 5-8

Mike Paulden

Lollipop Plots to Communicate Cost-Effectiveness Scenario Analyses Results pp. 9-12

Isaac Corro Ramos

Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects pp. 13-23

Becky Pennington, Sarah Davis and Holly Cranmer

Eladocagene Exuparvovec for the Treatment of Aromatic l-Amino Acid Decarboxylase Deficiency (AADCd): An Economic Evaluation from a US Perspective pp. 25-41

Rongrong Zhang, Thomas O’Connell, Berrin Monteleone, Yixi Teng, Paul Wuh-Liang Hwu, Paul Castellano and Ioannis Tomazos

Exploring the Generalizability of Foreign Cost-Effectiveness Analysis to Spain Using Data From a Scoping Review of Multinational Studies pp. 43-60

Lidia García-Pérez, Ignacio Abásolo-Alessón and Miguel Ángel Negrín-Hernández

The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment pp. 61-72

Jake Hitch, Gayathri Kumar, Paul Schneider, Nancy Devlin, Koonal Shah and David Mott

Cure Models: What is Meant by a Survival ‘Plateau’, and Do Experts Agree on What Constitutes One? pp. 73-82

Dan Jackson, Michael Sweeting, Robert Hettle, Binbing Yu, Neil Hawkins, Keith Abrams and Rose Baker

A Post-Market Economic Evaluation of Bortezomib, Lenalidomide and Dexamethasone Versus Pre-funding Standard of Care for Newly Diagnosed Multiple Myeloma Using Registry Data pp. 83-95

Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M. Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, Andrew Spencer and Zoe K. McQuilten

Comment on “Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective” by Marten J. Poley et al pp. 97-98

Alexander Allen, Alan Lovell, Ahmed Abdelsabour, Edward C. F. Wilson, G. J. Melendez-Torres and Dawn Lee

Reply to Comment on “Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective” pp. 99-100

Marten J. Poley, Nigel Armstrong, Huiqin Yang, Mubarak Patel, Lisa Stirk, Maiwenn J. Al and Isaac Corro Ramos

Correction: How do Health State Values Differ When Respondents Consider Adults Versus Children Living in Those States? A Systematic Review pp. 101-103

Ashwini De Silva, Alexander van Heusden, Zhongyu Lang, Nancy Devlin, Richard Norman, Kim Dalziel, Tessa Peasgood and Tianxin Pan